RT Journal Article
SR Electronic
T1 Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.09.23293865
DO 10.1101/2023.08.09.23293865
A1 Nakauma-González, J. Alberto
A1 Rijnders, Maud
A1 Noordsij, Minouk T. W.
A1 Martens, John W. M.
A1 van der Veldt, Astrid A.M.
A1 Lolkema, Martijn P. J.
A1 Boormans, Joost L.
A1 van de Werken, Harmen J. G.
YR 2024
UL http://medrxiv.org/content/early/2024/02/21/2023.08.09.23293865.abstract
AB APOBEC enzymes mutate specific DNA sequences and hairpin-loop structures, challenging the distinction between passenger and driver hotspot mutations. Here, we characterized 115 whole-genomes of metastatic urothelial carcinoma (mUC) to identify APOBEC mutagenic hotspot drivers. APOBEC-associated mutations were detected in 92% of mUC and were equally distributed across the genome, while APOBEC hotpot mutations (ApoHM) were enriched in open chromatin. Hairpin-loops were frequent targets of didymi (twins in Greek), two hotpot mutations characterized by the APOBEC mutational signature SBS2, in conjunction with an uncharacterized mutational context (Ap[C>T]), which was associated with DNA mismatch. Next, we developed a statistical framework that identified 0.40% of ApoHM as drivers of mUC, which affected known driver genes and non-coding regions near exons of potential novel driver genes. Our results and statistical framework were validated in independent cohorts of 23 non-metastatic UC and 3744 samples of 17 metastatic cancers, identifying cancer-type-specific drivers. Our study highlights the role of APOBEC in cancer development and may contribute to developing novel targeted therapy options for APOBEC-driven mUC.Competing Interest StatementJoost L. Boormans has received research support from Merck AG / Pfizer, Janssen and Merck Sharp & Dohme, and consultancy fees from Merck Sharp & Dohme, Bristol-Myers Squibb, Astellas, AstraZeneca, Ipsen and Janssen (all paid to the Erasmus MC Cancer Institute). Martijn P. J. Lolkema has received research support from JnJ, Sanofi, Astellas and MSD, and consultancy fees from Incyte, Amgen, JnJ, Bayer, Servier, Roche, INCa, Pfizer, Sanofi, Astellas, AstraZeneca, Merck Sharp & Dohme, Novartis, Julius Clinical and the Hartwig Medical Foundation (all paid to the Erasmus MC Cancer Institute). John W. M. Martens has received research support from Pfizer, Sanofi, GSK, Therawis Cergentis, and Philips (all paid to the Erasmus MC Cancer Institute) and one consultancy fee from Novartis. Astrid A.M. van der Veldt has received consultancy fees from BMS, MSD, Pfizer, Novartis, Eisai, Sanofi, Pierre Fabre, Ipsen and Roche (all paid to the Erasmus MC Cancer Institute). J. Alberto Nakauma-Gonzalez, Maud Rijnders, Minouk Noordsij and Harmen J. G. van de Werken declare no competing interests.Funding StatementThe Stichting Dutch Uro-Oncology Study (DUOS) group and the Daniel den Hoed Foundation supported this research. J. Alberto Nakauma-Gonzalez was collectively supported by the national funding organization the Dutch Cancer Society (KWF, the Netherlands) under the framework of the ERA-NET TRANSCAN-2 initiativeAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols of patients analyzed in this publication have been approved by the corresponding authorities at the time of access granted by HMF and the NCBI dbGAP.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAvailability of data and materials WGS, RNA-seq and clinical data from mUC and mBC are available through the Hartwig Medical Foundation at https://www.hartwigmedicalfoundation.nl, under request numbers DR-041, DR-026 and DR-131, respectively. For mUC, samples that were previously analyzed (DR-031) by Nakauma et. al, 2022, were retrieved from DR-131. WGS data from primary UC was requested to the NCBI dbGAP and granted access through request #33427. ChIPseq data experiments are freely available through The ENCODE Project Consortium and the Roadmap Epigenomics Consortium on the ENCODE portal (https://www.encodeproject.org). The scripts, including the algorithm to find hairpin-loops and estimate the thermodynamic stability have been deposited in a public repository available at https://github.com/ANakauma/ApobecHM_drivers. Other scripts used for processing sequencing data can be found at https://github.com/J0bbie/R2CPCT and https://github.com/hartwigmedical/hmftools